During this project, the investigators want to explore in vitro changes in basal cells and the crosstalk with residing immune cells as potential pathogenic mechanisms in CRSwNP vs healthy controls by using surgically resected patient samples.
Patients over the age of 18
Males and females
CRSwNP
AR
Smoker, or < 1-year ex-smoker
Underlying systematic pathology (Morbus Wegener or Churg Strauss Syndrome for example)
CRSwNP patients: Inclusion Criteria: * Patients over the age of 18 * Males and females * Patient with symptoms of chronic rhinosinusitis * Presence of nasal polyps Exclusion Criteria: * AR * Smoker, or \< 1-year ex-smoker * Patient with cystic fibrosis * Only the presence of an antrochoanal polyp * Underlying systematic pathology (Morbus Wegener or Churg Strauss Syndrome for example) AR patients: Inclusion criteria: * Patients over the age of 18 * Males and females * Patients with AR symptoms Exclusion criteria: * CRSwNP * Smoker, or \< 1-year ex-smoker * Underlying systematic pathology (Morbus Wegener or Churg Strauss Syndrome for example)
Cohort
Cross-sectional
Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation
Procedure/SurgeryConchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.
Functional differences between epithelial/basal cells from CRSwNP samples in comparison to healthy controls assessed with functional assays.
Multiple techniques and functional assays will be used to fully investigate the functional differences between epithelial/basal cells isolated from healthy and CRSwNP samples. The differences in barrier composition will be assessed through TEER measurements (Ω × cm2) and FD4 permeability assays (ng/ml). Moreover, barrier composition is investigated by examining differences in membrane markers and junction expression through immunofluorescence and RT-qPCR. Finally, primary isolated cells will be used to assess protein levels through immunostainings, flow cytometry, and Western blots.
Characterization of differences in gene expression profiles and epithelial populations in/between CRSwNP and healthy controls assessed with different sequencing techniques.
To characterize differences in gene expression, or identify specific genes/cell populations that can contribute to CRSwNP, scRNA-sequencing will be performed, as well as bulk RNA sequencing. Depending on these results, specific triggers or receptors that can contribute to CRSwNP will be investigated by stimulation experiments. Besides, the effect on epigenetic imprinting before and after stimulation by performing ATAC-sequencing or DNA methylation profiling will be studied as well.
Changes and interactions in the basal and regulatory T-cell axis between healthy and CRSwNP-isolated cells will be studied through co-culture experiments.
The interaction between basal and regulatory T cells in relation to homeostasis and regeneration, and how this might change or contribute in/to CRSwNP will be investigated by co-culturing these cells. This will be assessed through the analysis of the supernatants using the Olink platform to investigate cytokines etc. Besides, there will be bulk RNA sequencing to look at changes in gene expression, as well as proliferation and growth assays to see the effect of T cells on basal cells and vice versa. To look at functional changes we can asses different functional assays and techniques (see outcome 1).
Click on the lead sponsor to view all of their trials.
Universitaire Ziekenhuizen KU Leuven
Lead sponsor
Regeneron Pharmaceuticals
Collaborator
